---
document_datetime: 2026-01-22 12:46:27
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/bavencio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: bavencio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2304842
conversion_datetime: 2026-01-26 20:54:48.239239
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.70.0
  docling-core: 2.60.2
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Bavencio

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 16/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313566                     | variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z - To more accurately describe the appearance of active substance, starting material, intermediate or reagent - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.d Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) -   |            |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type II / EMA/VR/0000279701 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add 'cytokine release syndrome' to the list of adverse drug reactions (ADRs) with frequency uncommon, based on a safety assessment report. In addition, the MAH                                                                                                                                                                                                                 | 27/11/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                       | took the opportunity to introduce updates to the PI that include warning on polysorbate as well as statements on the use of the Patient Card in addition to administrative and editorial changes to the PI.                                                                                                                                                                                                                                                     |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type II / EMA/VR/0000261861 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 4.8 of the SmPC in order to add 'Gastritis' to the list of adverse drug reactions (ADRs) with frequency 'Not known' based on postmarketing data and literature. The Package Leaflet is updated accordingly. The | 27/11/2025 |     | SmPC and PL |
| Variation type II / EMA/VR/0000289992 | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.c The product is a biological/immunological medicinal product and the change requires an assessment of comparability - Accepted                                                                                                                   | 23/10/2025 | N/A |             |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.e.3 Change in test procedure for the immediate packaging of the finished product - B.II.e.3.b Other changes to a test procedure (including replacement or addition) - Accepted B.II.e.4 Change in shape or dimensions of the container or closure (immediate packaging) - B.II.e.4.c Sterile medicinal products - Accepted B.II.e.1.a Qualitative and quantitative composition - B.II.e.1.a.3 Sterile medicinal products and biological/ immunological medicinal products - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.c Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by   |            |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type II / EMA/VR/0000244307 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/09/2025 |

<div style=\"page-break-after: always\"></div>

|                     | the competent authority - Accepted Submission of the final report from study MS100070-0031 listed as a category 3 PASS in the RMP. This is a non-interventional cohort efficacy and safety study to assess the characteristics and management of patients with Merkel cell carcinoma (MCC) in Germany.                                                                                                                                                                                                                                                                                                                                                                             |            |     |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB / | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process | 25/07/2025 | N/A | EMA/VR/0000285637 |

<div style=\"page-break-after: always\"></div>

|                                       | changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000272517 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.i Where there is no monograph in the European Pharmacopoeia or the national pharmacopoeia of a Member State for the active substance, a change in specification from in-house to a non-official Pharmacopoeia or a Pharmacopoeia of a third country - Accepted | 28/05/2025 | N/A |